Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments

Final draft guidance

Final draft guidance (PDF 258 KB)

Committee papers (PDF 811 KB)

Public committee slides (PDF 674 KB)

Draft guidance

Draft guidance (PDF version) (PDF 280 KB)

Draft guidance (online commenting)

Committee papers (PDF 8.64 MB)

Final scope (PDF 211 KB)

Final stakeholder list (PDF 172 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 219 KB)

Draft matrix post referral (PDF 167 KB)